- Home
- ICU vs CDT Comparison
ICU vs CDT Comparison
Compare ICU & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICU
- CDT
- Stock Information
- Founded
- ICU 2018
- CDT 2019
- Country
- ICU United States
- CDT United States
- Employees
- ICU N/A
- CDT N/A
- Industry
- ICU Biotechnology: Pharmaceutical Preparations
- CDT Biotechnology: Pharmaceutical Preparations
- Sector
- ICU Health Care
- CDT Health Care
- Exchange
- ICU Nasdaq
- CDT Nasdaq
- Market Cap
- ICU 10.3M
- CDT 10.9M
- IPO Year
- ICU N/A
- CDT N/A
- Fundamental
- Price
- ICU $2.19
- CDT $0.09
- Analyst Decision
- ICU
- CDT
- Analyst Count
- ICU 0
- CDT 0
- Target Price
- ICU N/A
- CDT N/A
- AVG Volume (30 Days)
- ICU 24.8K
- CDT 12.0M
- Earning Date
- ICU 11-13-2024
- CDT 11-26-2024
- Dividend Yield
- ICU N/A
- CDT N/A
- EPS Growth
- ICU N/A
- CDT N/A
- EPS
- ICU N/A
- CDT N/A
- Revenue
- ICU $68,000.00
- CDT N/A
- Revenue This Year
- ICU N/A
- CDT N/A
- Revenue Next Year
- ICU $344.44
- CDT N/A
- P/E Ratio
- ICU N/A
- CDT N/A
- Revenue Growth
- ICU N/A
- CDT N/A
- 52 Week Low
- ICU $1.88
- CDT $0.08
- 52 Week High
- ICU $42.93
- CDT $7.83
- Technical
- Relative Strength Index (RSI)
- ICU 25.85
- CDT 38.86
- Support Level
- ICU $1.88
- CDT $0.09
- Resistance Level
- ICU $2.81
- CDT $0.11
- Average True Range (ATR)
- ICU 0.30
- CDT 0.01
- MACD
- ICU -0.04
- CDT -0.00
- Stochastic Oscillator
- ICU 18.58
- CDT 16.41
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses.
About CDT Conduit Pharmaceuticals Inc.
Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being, prioritized by leading biopharmaceutical companies in order to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready in autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.